R&D of vaccine targeted at COVID-19 Delta variant has been incorporated into “Pioneer Program” of Zhejiang Province for rolling submission to CDE.
As declared by Zhejiang Provincial Department of Science and Technology on November 26, 2021, R&D of COVID-19 Vaccine Targeted at Delta Variant has been incorporated into Key “Pioneer” R&D Projects of Zhejiang Province for the year of 2022. This project is initiated by Ningbo Rong’an Biological Pharmaceutical Co., Ltd through cooperation with Zhejiang Provincial Center for Disease Control and Prevention. As the collaborator, Ningbo Rong’an Biological Pharmaceutical Co., Ltd is accelerating the development of inactivated COVID-19 vaccine targeted at Delta variant. So far, it has entered the non-clinical animal evaluation stage, including animal safety evaluation, immunogenicity evaluation and protection evaluation. In the near future, it will proceed with rolling submission of relevant information to Center for Drug Evaluation (CDE), NMPA.
Zhejiang Provincial Center for Disease Control and Prevention took the lead in successful separation of Delta variant. Early in May, 2021, Ningbo Rong’an Biological Pharmaceutical Co., Ltd participated in this project for development of vaccine in view of genetic characteristics of Delta variant. It is mainly engaged in study of major preparation techniques and quality control criteria, evaluation and study of validity and safety of vaccine for animals tested, application for clinical test and study of clinical tests of vaccine approved.
Ningbo Rong’an Biological Pharmaceutical Co., Ltd comes to the top in China in t concluerms of its R&D and industrialization level of vaccine. The rabies vaccine for human use (Vero cell) as produced by the company came to the second position in China in terms of lot release and sales revenue in 2020. In May, 2021, Ningbo Rong’an Biological Pharmaceutical Co., Ltd concluded a cooperation agreement with Zhejiang Provincial Center for Disease Control and Prevention to develop the 2nd generation of COVID-19 vaccine targeted at Delta variant. It is one of the first companies engaged in R&D of vaccine through separation of Delta variant.
As one of participants of R&D Project of COVID-19 Vaccine Targeted at Delta Variant as listed, Ningbo Rong’an Biological Pharmaceutical Co., Ltd is planning to initiate clinical test in the coming year as per overall planning of AIM Vaccine to develop high-quality vaccine based on its superior advantages over science and technology. This aims to win the battle for prevention and elimination of COVID-19 epidemics.
(Pictures herein shows advanced bio-safety workshop of inactivated COVID-19 vaccine located at Ningbo Rong’an Biological Pharmaceutical Co., Ltd)
Zhejiang Provincial Center for Disease Control and Prevention took the lead in successful separation of Delta variant. Early in May, 2021, Ningbo Rong’an Biological Pharmaceutical Co., Ltd participated in this project for development of vaccine in view of genetic characteristics of Delta variant. It is mainly engaged in study of major preparation techniques and quality control criteria, evaluation and study of validity and safety of vaccine for animals tested, application for clinical test and study of clinical tests of vaccine approved.
Ningbo Rong’an Biological Pharmaceutical Co., Ltd comes to the top in China in t concluerms of its R&D and industrialization level of vaccine. The rabies vaccine for human use (Vero cell) as produced by the company came to the second position in China in terms of lot release and sales revenue in 2020. In May, 2021, Ningbo Rong’an Biological Pharmaceutical Co., Ltd concluded a cooperation agreement with Zhejiang Provincial Center for Disease Control and Prevention to develop the 2nd generation of COVID-19 vaccine targeted at Delta variant. It is one of the first companies engaged in R&D of vaccine through separation of Delta variant.
As one of participants of R&D Project of COVID-19 Vaccine Targeted at Delta Variant as listed, Ningbo Rong’an Biological Pharmaceutical Co., Ltd is planning to initiate clinical test in the coming year as per overall planning of AIM Vaccine to develop high-quality vaccine based on its superior advantages over science and technology. This aims to win the battle for prevention and elimination of COVID-19 epidemics.
(Pictures herein shows advanced bio-safety workshop of inactivated COVID-19 vaccine located at Ningbo Rong’an Biological Pharmaceutical Co., Ltd)
